FacebookTwitterGoogle+RedditEmail

The Big HRT

by MARTHA ROSENBERG

A reduction in a jury award for a drug that caused cancer from $134 million to $58 million would not normally be cause to rejoice. But it has not been a normal year for hormone maker Wyeth.

The Madison, N.J. based drug company faces 5,300 Prempro and Premarin related law suits in addition to the one it just lost–but with damages reduced–in Reno, NV brought by three women with breast cancer.

Wyeth had asked Washoe District Judge Robert Perry for a mistrial.

Selling a product that’s proven to cause cancer isn’t easy for Wyeth.

In January, it announced it was selling the one million square-foot Rouses Point, N.Y plant where it made its horse-urine derived drugs and employed 900 and cutting a full ten percent of its work force.

Nor is the Food and Drug Administration (FDA) rubber stamping new drugs from the company which made fenfluramine/phentermine and some say has a “safety second” culture.

Last year it rejected Wyeth’s osteoporosis drug, bazedoxifene, because of stroke and blood clot problems, schizophrenia drug, bifeprunox, because it was not as effective as other drugs on the market and menopause drug, Pristiq, because of serious heart or liver complications experienced by trial participants.

The FDA is “establishing monopolies” by rejecting drugs just because they’re inferior to existing ones growled outgoing Wyeth CEO Bob Essner when bifeprunox was not approved. After all, the public liked Vioxx and Vytorin just fine and they weren’t better than their predecessors, he might have been thinking.
No wonder Wyeth lawyers have been browbeating the FDA, successfully it turns out, to regulate pharmacy compounded bioidentical hormones that have unseated its products in many women’s medicine chests.

Wyeth is not alone in hoping for an HRT comeback.

Since HRT was found by the Women’s Health Initiative in 2002 to cause a 26 percent increased risk of breast cancer, 29 percent increased risk of heart attack, 41 percent increased risk of stroke and 100 percent increased risk of blood clots, a study in the January issue of Cancer Epidemiology, Biomarkers and Prevention found the cancers also move quickly.

Women who took combined estrogen/progestin hormone-replacement therapy for just three years had four times the usual risk of lobular breast cancer which accounts for about 10 percent of invasive breast cancer.

The effect of millions of HRT users saying, “You want us to take WHAT?” after the WHI study–75 percent quit–was also dramatic. There was an 8.6 percent reduction in overall breast cancer between 2001 and 2004 and 14.7 reduction for estrogen-receptor positive breast cancer.

But “studies” by doctors who don’t want to give up the HRT gravy train appear with increasing regularity, promoting results that seek to reverse or spin the WHI findings.

HRT actually protects against heart disease and reduces calcification of the arteries–two original, disproved HRT selling points–say the authors of the new crop of “timing hypothesis/therapeutic window of opportunity” analyses, hoping the memory of the American public is as short as their practice’s funds without trumped up HRT profits.

Researchers even resuscitated the discredited claim that HRT protects against dementia at a meeting of the American Academy of Neurology last year. And there are rumblings that HRT’s ability to lower colon cancer could be of value. (Viz: HRT causes breast cancer, heart attack, stroke and blood clots but you might not get colon cancer!)

Of course some doctors have noted the creeping HRT revisionism.

Enthusiasm for the Yes But studies “far exceeds the science” and does not “alter current recommendations that hormone therapy should never be used to prevent heart disease,” says Dr. Helen Roberts, senior lecturer in women’s health at Auckland University. For one thing, “the risk of stroke was elevated regardless of how many years had elapsed since menopause,” she says of the new studies.

But others like the American Association of Clinical Endocrinologists (AACE) have jumped on the HRT bandwagon.

“This is an important and meaningful analysis for women who can benefit from Hormone Replacement Therapy,” said Richard Hellman, AACE President about a study which indicated HRT did not elevate cardiovascular disease risk in some women.

And a position paper on the AACE site says, “Given the powerful effects of estrogen therapy in relieving menopausal symptoms, we believe that physicians may safely counsel women to use estrogen for the relief of menopausal symptoms.”

Some suggest Wyeth money is behind the AACE position.

After all, Hellman also came out for controversial diabetes drug Avandia when the FDA questioned the drug’s safety. “There is still not a good scientific basis for assessing the drug’s safety in all patients. But, we can say, if there is an increased risk for a heart attack, it appears to be a relatively small risk,” he wrote on the AACE site.

And even though he added the organization has “no financial ties to the company, GlaxoSmithKline that manufactures Avandia,” AACE’s annual report for 2006-2007 thanks GlaxoSmithKline four times for its financial support.

Wyeth money could help for future court cases.

 

 

 

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

Weekend Edition
December 09, 2016
Friday - Sunday
Jeffrey St. Clair
Roaming Charges: Nasty As They Wanna Be
Henry Giroux
Trump’s Second Gilded Age: Overcoming the Rule of Billionaires and Militarists
Andrew Levine
Trump’s Chumps: Victims of the Old Bait and Switch
Chris Welzenbach
The Forgotten Sneak Attack
Lewis Lapham
Hostile Takeover
Joshua Frank
This Week at CounterPunch: More Hollow Smears and Baseless Accusations
Paul Street
The Democrats Do Their Job, Again
Vijay Prashad
The Cuban Revolution: Defying Imperialism From Its Backyard
Michael Hudson - Sharmini Peries
Orwellian Economics
Erin McCarley
American Nazis and the Fight for US History
Mark Ames
The Anonymous Blacklist Promoted by the Washington Post Has Apparent Ties to Ukrainian Fascism and CIA Spying
Yoav Litvin
Resist or Conform: Lessons in Fortitude and Weakness From the Israeli Left
Conn Hallinan
India & Pakistan: the Unthinkable
Andrew Smolski
Third Coast Pillory: Nativism on the Left – A Realer Smith
Joshua Sperber
Trump in the Age of Identity Politics
Brandy Baker
Jill Stein Sees Russia From Her House
Katheryne Schulz
Report from Santiago de Cuba: Celebrating Fidel’s Rebellious Life
Nelson Valdes
Fidel and the Good People
Norman Solomon
McCarthy’s Smiling Ghost: Democrats Point the Finger at Russia
Renee Parsons
The Snowflake Nation and Trump on Immigration
Margaret Kimberley
Black Fear of Trump
Michael J. Sainato
A Pruitt Running Through It: Trump Kills Nearly Useless EPA With Nomination of Oil Industry Hack
Ron Jacobs
Surviving Hate and Death—The AIDS Crisis in 1980s USA
David Swanson
Virginia’s Constitution Needs Improving
Louis Proyect
Narcos and the Story of Colombia’s Unhappiness
Paul Atwood
War Has Been, is, and Will be the American Way of Life…Unless?
John Wight
Syria and the Bodyguard of Lies
Richard Hardigan
Anti-Semitism Awareness Act: Senate Bill Criminalizes Criticism of Israel
Kathy Kelly
See How We Live
David Macaray
Trump Picks his Secretary of Labor. Ho-Hum.
Howard Lisnoff
Interview with a Political Organizer
Yves Engler
BDS and Anti-Semitism
Adam Parsons
Home Truths About the Climate Emergency
Brian Cloughley
The Decline and Fall of Britain
Eamonn Fingleton
U.S. China Policy: Is Obama Schizoid?
Graham Peebles
Worldwide Air Pollution is Making us Ill
Joseph Natoli
Fake News is Subjective?
Andre Vltchek
Tough-Talking Philippine President Duterte
Binoy Kampmark
Total Surveillance: Snooping in the United Kingdom
Guillermo R. Gil
Vivirse la película: Willful Opposition to the Fiscal Control Board in Puerto Rico
Patrick Bond
South Africa’s Junk Credit Rating was Avoided, But at the Cost of Junk Analysis
Clancy Sigal
Investigate the Protesters! A Trial Balloon Filled With Poison Gas
Pierre Labossiere – Margaret Prescod
Human Rights and Alternative Media Delegation Report on Haiti’s Elections
Charles R. Larson
Review:  Helon Habila’s The Chibok Girls: the Boko Haram Kidnappings and Islamist Militancy in Nigeria
David Yearsley
Brahms and the Tears of Britain’s Oppressed
FacebookTwitterGoogle+RedditEmail